{"title":"Paired CSF-Plasma Analyte Signal Contrasts Across Alzheimer's Disease Clinical Stages and MCI-to-Dementia Conversion.","authors":"Yuepeng Deng, Dandan Chen, Haolin Yin, Zihao Lu, Xiaohe Tian, Qiyong Gong","doi":"10.3390/biomedicines14102407","DOIUrl":"10.3390/biomedicines14102407","url":null,"abstract":"<p><p><b>Background:</b> Cerebrospinal fluid (CSF) and plasma biomarkers provide complementary information about Alzheimer's disease (AD), but matched analytes are commonly evaluated separately. We investigated whether relative CSF-plasma analyte signals were associated with AD clinical stage and subsequent conversion from mild cognitive impairment (MCI) to AD dementia. <b>Methods:</b> We analyzed paired CSF and plasma NULISAseq data from 1199 Alzheimer's Disease Neuroimaging Initiative participants. For 125 shared analyte readouts, ΔNPQ was defined as the within-participant difference between CSF and plasma normalized protein quantifications. Clinical-stage associations were evaluated using covariate-adjusted models. In 547 participants with baseline MCI, we examined subsequent dementia conversion and compared matched CSF-only, plasma-only, ΔNPQ, and joint CSF-plasma representations. <b>Results:</b> Fourteen readouts mapping to eight gene-level targets were associated with more advanced clinical stage after false-discovery-rate correction, involving amyloid/tau, synaptic, astroglial, cholinergic, and neuroaxonal processes. During a median follow-up of 3.0 years, 203 participants with MCI converted to AD dementia. A cross-sectionally derived six-analyte ΔNPQ score was associated with subsequent conversion after adjustment for demographic, genetic, and baseline clinical characteristics (hazard ratio per standard deviation, 1.64; 95% confidence interval, 1.38-1.96). The joint CSF-plasma model yielded the largest estimated improvement in discrimination. After additional adjustment for amyloid/tau biomarkers, the association between ΔNPQ and dementia conversion was attenuated. <b>Conclusions:</b> Relative CSF-plasma analyte patterns are associated with AD clinical stage and subsequent dementia conversion in MCI. Paired-biofluid analysis provides a complementary framework for characterizing disease-associated molecular heterogeneity, rather than a demonstrably superior prognostic model.</p>","PeriodicalId":8937,"journal":{"name":"Biomedicines","volume":"14 10","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13701971/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149262057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BiomedicinesPub Date : 2026-10-21DOI: 10.3390/biomedicines14102403
Shanshan Xu, Congtian Fan, Haidong Chen, Dan Chen, Jie Lu, Jianyong Xu, Hua Huang, Yu Jiang
{"title":"<i>Fagopyrum cymosum</i> Extract Improves Mitochondrial Function and Reduces Colonic Inflammation in Ulcerative Colitis by Targeting the PI3K/Akt/FOXO3A Pathway.","authors":"Shanshan Xu, Congtian Fan, Haidong Chen, Dan Chen, Jie Lu, Jianyong Xu, Hua Huang, Yu Jiang","doi":"10.3390/biomedicines14102403","DOIUrl":"10.3390/biomedicines14102403","url":null,"abstract":"<p><p><b>Background/Objectives:</b> Ulcerative colitis (UC) is a chronic inflammatory bowel disease with limited therapeutic options. Although <i>Fagopyrum cymosum</i> exhibits anti-inflammatory and antioxidant activities, its efficacy in UC and the underlying mechanisms are not well defined. Here, we evaluate whether <i>Fagopyrum cymosum</i> extract (RFC) alleviates DSS-induced colitis in mice and investigate the involvement of the PI3K/Akt/FOXO3A pathway. <b>Methods:</b> C57BL/6 mice received 2% DSS for 14 days, followed by 7-day intragastric RFC (low: 234 mg/kg; medium: 468 mg/kg; high: 936 mg/kg) with 5-ASA (200 mg/kg) as a control. Disease activity index (DAI), colon length, histopathology, bacterial translocation, and organ indices were assessed. Colonic mitochondrial membrane potential (JC-1), ATP, oxidative markers (SOD, GSH-px, MDA), and cytokines (IL-6, IL-1β, TNF-α) were measured. Network pharmacology, qPCR, and Western blotting were performed, alongside a PI3K agonist (740Y-P) rescue experiment. <b>Results:</b> RFC dose-dependently improved weight loss, DAI, colon shortening, mucosal damage, bacterial loads, and immune organ indices. It restored mitochondrial function, reduced MDA, elevated SOD/GSH-px, and suppressed inflammatory cytokines. Mechanistically, RFC inhibited PI3K/Akt phosphorylation and upregulated FOXO3A, effects reversed by 740Y-P, which also abolished RFC's protective, antioxidant, and anti-inflammatory actions. <b>Conclusions:</b> RFC ameliorates DSS-induced colitis by suppressing PI3K/Akt signaling and upregulated FOXO3A expression, thereby preserving mitochondrial function, reducing oxidative stress, and alleviating colonic inflammation. The PI3K/Akt/FOXO3A axis emerges as a promising therapeutic node, and RFC merits further evaluation for UC treatment.</p>","PeriodicalId":8937,"journal":{"name":"Biomedicines","volume":"14 10","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13701870/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149261885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BiomedicinesPub Date : 2026-10-21DOI: 10.3390/biomedicines14102402
Zaina Nafees, Sara S N Mohammed, Grisilda Vidya Bernhardt, Suresh Kumar
{"title":"Therapeutic Interventions in Niemann-Pick Disease Type C: A Systematic Review of Clinical Outcomes and Safety.","authors":"Zaina Nafees, Sara S N Mohammed, Grisilda Vidya Bernhardt, Suresh Kumar","doi":"10.3390/biomedicines14102402","DOIUrl":"10.3390/biomedicines14102402","url":null,"abstract":"<p><p><b>Background</b>: Niemann-Pick disease type C (NPC) is a rare, progressive lysosomal storage disorder characterized by impaired intracellular lipid trafficking, leading to systemic, neurological, and psychiatric manifestations. Although supportive care was historically the main treatment approach, several disease-modifying and symptomatic therapies have recently emerged. This systematic review aimed to evaluate the efficacy and safety of current therapeutic strategies for NPC. <b>Methods</b>: A systematic literature search was conducted in PubMed, Scopus, and ClinicalTrials.gov from inception to 1 August 2026. Eligible studies included randomized controlled trials and interventional clinical studies involving patients with NPC of any age or sex. Interventions included miglustat, arimoclomol, N-acetyl-L-leucine (NALL), hydroxypropyl-β-cyclodextrin (HPβCD), vorinostat, N-acetylcysteine (NAC), efavirenz, nizubaglustat and other therapeutic strategies. Outcomes included neurological progression, clinical severity scores, ataxia measures, quality of life, biomarkers, cognition, and adverse events. Due to heterogeneity in study designs and outcome measures, findings were synthesized narratively. <b>Results</b>: Twenty-four studies representing approximately 475 participants, after removal of documented cohort overlap, were included. Miglustat showed evidence of neurological stabilization, particularly when initiated early, with mainly gastrointestinal adverse effects. Arimoclomol demonstrated evidence of slowing neurological progression and was generally well tolerated, although longer-term safety and effectiveness data remain necessary. NALL improved ataxia-related symptoms and was generally well tolerated. HPβCD demonstrated biological target engagement, including changes in cholesterol-related biomarkers, but clinical findings were mixed: uncontrolled intrathecal and intravenous studies suggested stabilization or improvement, whereas controlled evidence was less supportive. Hearing impairment remained an important safety concern. Evidence for vorinostat, NAC, efavirenz, and nizubaglustat was limited by small samples and early-phase or uncontrolled designs. <b>Conclusions</b>: The available evidence most consistently supports miglustat, arimoclomol, and NALL for stabilizing neurological progression or improving functional outcomes in NPC. However, differences in study design, outcome measures, and follow-up preclude direct comparison between therapies. HPβCD remains investigational because its biological activity has not translated into consistent controlled clinical benefit and requires careful safety monitoring. Larger controlled studies using standardized clinical outcomes and reliable biomarkers are needed to define long-term effectiveness and optimize treatment selection.</p>","PeriodicalId":8937,"journal":{"name":"Biomedicines","volume":"14 10","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13702622/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149262105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BiomedicinesPub Date : 2026-10-21DOI: 10.3390/biomedicines14102400
Anna Pawłowska-Łachut, Wiktoria Skiba, Paulina Pieniądz-Feculak, Karolina Włodarczyk-Ciekańska, Dorota Suszczyk, Jakub Łyczba, Monika Bilska, Michalina Kazimierczuk, Józef Kotarski, Ewa Boniewska-Bernacka, Jacek Tomaszewski, Iwona Wertel
{"title":"Phenotypic Landscape of Programmed Death and TIGIT/CD155/DNAM-1 Pathways in NK Cells in Ovarian Cancer.","authors":"Anna Pawłowska-Łachut, Wiktoria Skiba, Paulina Pieniądz-Feculak, Karolina Włodarczyk-Ciekańska, Dorota Suszczyk, Jakub Łyczba, Monika Bilska, Michalina Kazimierczuk, Józef Kotarski, Ewa Boniewska-Bernacka, Jacek Tomaszewski, Iwona Wertel","doi":"10.3390/biomedicines14102400","DOIUrl":"10.3390/biomedicines14102400","url":null,"abstract":"<p><p><b>Objectives</b>: Ovarian cancer (OC) is the gynecological malignancy with the highest mortality rate. Preclinical studies have shown that dual blockade of immune checkpoint proteins (ICPs), such as PD-1 and TIGIT, may be beneficial for OC patients. Thus, the aim of this study was to evaluate the expression of PD-1, TIGIT, and DNAM-1 in NK cells in three OC environments-i.e., peripheral blood (PB), peritoneal fluid (PF), and tumor tissue (TT)-and their soluble forms in plasma and PF to explore their clinical significance. <b>Methods</b>: The expression of ICPs on NK cells was analyzed via flow cytometry. The concentrations of soluble forms of these ICPs were measured in plasma and PF via ELISA. The obtained results were correlated with the clinicopathological features of OC patients. <b>Results</b>: We observed an increased percentage of PD-1<sup>+</sup> NK cells in tumor tissue (<i>p</i> < 0.05), as well as TIGIT<sup>+</sup> (<i>p</i> < 0.001) and DNAM-1<sup>+</sup> NK cells in PF of patients with OC (<i>p</i> < 0.05). Soluble PD-1 (sPD-1) concentration was higher in PF than in plasma (<i>p</i> < 0.0001) and higher in plasma of OC patients than in controls (<i>p</i> < 0.001), while soluble TIGIT (sTIGIT) levels were elevated in plasma of OC patients compared with controls (<i>p</i> < 0.05). NK cell phenotypic alterations were also associated with selected clinicopathological features of OC (i.e., FIGO disease advancement, tumor type according to Kurman and Shih, and grade). The percentage of NK cells in PF was positively associated with age (<i>p</i> < 0.01) and negatively associated with BMI (<i>p</i> < 0.05). <b>Conclusions</b>: OC is characterized by distinct compartment-specific patterns of PD-1, TIGIT, and DNAM-1 expression on NK cells, accompanied by altered soluble ICP profiles. These phenotypic patterns may help define the immune landscape of the ovarian cancer microenvironment.</p>","PeriodicalId":8937,"journal":{"name":"Biomedicines","volume":"14 10","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13702272/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149261835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Exploratory Interim Analysis of Serial Plasma and Single-Follicle Follicular Fluid Oxidation-Reduction Potential During Fertility Treatment.","authors":"Aris Kaltsas, Stamatis Papaharitou, Kyriakos Papanikolaou, Aristea Sidiropoulou, Katerina Chatzimeletiou","doi":"10.3390/biomedicines14102404","DOIUrl":"10.3390/biomedicines14102404","url":null,"abstract":"<p><p><b>Background/Objectives:</b> This exploratory interim analysis examined associations between serial plasma oxidation-reduction potential (ORP) and single-follicle follicular-fluid (FF) ORP during fertility treatment. Between-visit measurements and cycle-level outcomes were also described. <b>Methods:</b> In 31 cycles from 29 women, plasma was sampled prospectively at cycle day 2 (D2), D6, and pre-trigger, and FF from one follicle at retrieval. Fresh samples were measured in duplicate (MiOXSYS); only means were available. All analyses were post hoc and used Spearman correlations, an intraclass correlation coefficient (ICC), and mixed models with within-family adjustment. <b>Results:</b> Plasma-FF correlations were 0.580 at D2 (<i>n</i> = 25; 95% confidence interval [CI], 0.178-0.839), 0.715 at D6 (<i>n</i> = 23; CI, 0.350-0.924), and 0.866 pre-trigger (<i>n</i> = 23; CI, 0.679-0.941). All Holm-adjusted <i>p</i> values were ≤0.0027. In 21 women with complete profiles, between-visit correlations were 0.703-0.856 (ICC, 0.788; CI, 0.617-0.872). The mixed-model pre-trigger minus D6 difference was 6.6 mV (CI, 0.6-12.6; Holm-adjusted <i>p</i> = 0.0939). No visit contrast or main ORP-outcome association met its adjusted threshold. <b>Conclusions:</b> Plasma and FF ORP were associated in this small interim cohort. Neither biological stability nor a true temporal change was established, and assay precision, agreement, and prognostic value remain unknown. Clinical application is not supported.</p>","PeriodicalId":8937,"journal":{"name":"Biomedicines","volume":"14 10","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13702690/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149261866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BiomedicinesPub Date : 2026-10-21DOI: 10.3390/biomedicines14102405
Paola Bagnoli
{"title":"The Translational Value of Preclinical Research: Lessons from More Than Forty Years of Retinal Research.","authors":"Paola Bagnoli","doi":"10.3390/biomedicines14102405","DOIUrl":"10.3390/biomedicines14102405","url":null,"abstract":"<p><p>The present paper is based on a long personal experience of research on the retina. Over almost forty years, questions that were originally pursued as curiosity-driven physiology progressively acquired unexpected translational implications. The retina provides a particularly instructive setting in which to examine translational potential because its accessible and highly organized neural and vascular architecture has allowed mechanisms identified in experimental models to be tested as potential therapeutic targets. Three research trajectories from our laboratory are discussed as examples of different translational outcomes. Studies of the somatostatinergic system illustrate how a strong mechanistic rationale and convincing preclinical efficacy may not necessarily translate into comparable clinical benefit. Investigations of the uPA/uPAR system and its pharmacological inhibition show how a candidate that does not reach clinical application may nevertheless provide durable insight into disease mechanisms and identify biologically relevant pathways. Conversely, studies of β-adrenoceptor signaling and propranolol in retinopathy of prematurity illustrate how drug repurposing can shorten the distance between experimental evidence and clinical investigation, while still leaving important questions about dose, safety, and delivery. These experiences also highlight model selection, disease stage, pharmacokinetics, tissue exposure, reproducibility and patient heterogeneity as critical determinants of translational success. Taken together, my experience of research on the retina suggests that translation should be viewed not as a one-way progression from bench to bedside, but as an iterative process in which experimental findings, clinical outcomes and even unsuccessful therapeutic attempts continuously reshape biological questions.</p>","PeriodicalId":8937,"journal":{"name":"Biomedicines","volume":"14 10","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13701875/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149262016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BiomedicinesPub Date : 2026-10-21DOI: 10.3390/biomedicines14102408
Lorenzo Giovannico, Giuseppe Fischetti, Domenico Parigino, Luca Savino, Claudia Leo, Giuseppe Cristiano, Ilaria Paradiso, Federica Ferrara, Francesca Broggini, Carlo Mancini, Massimiliano Carrozzini, Massimo Padalino, Tomaso Bottio
{"title":"Axillary Dacron Graft Versus Direct Femoral Arterial Cannulation for Peripheral VA-ECMO After Heart Transplantation: A Single-Center Cohort Study.","authors":"Lorenzo Giovannico, Giuseppe Fischetti, Domenico Parigino, Luca Savino, Claudia Leo, Giuseppe Cristiano, Ilaria Paradiso, Federica Ferrara, Francesca Broggini, Carlo Mancini, Massimiliano Carrozzini, Massimo Padalino, Tomaso Bottio","doi":"10.3390/biomedicines14102408","DOIUrl":"10.3390/biomedicines14102408","url":null,"abstract":"<p><p><b>Background/Objectives:</b> Primary graft dysfunction (PGD) remains a major cause of early morbidity and mortality after heart transplantation, and peripheral veno-arterial extracorporeal membrane oxygenation (VA-ECMO) represents an established rescue therapy for severe cases. Although direct femoral arterial cannulation is commonly used because of its rapid deployment, axillary artery cannulation through a Dacron graft provides antegrade arterial perfusion and may represent an alternative approach. This study compared early clinical outcomes and cannulation-related complications between these two arterial cannulation strategies. <b>Methods:</b> In this retrospective single-center observational study, 42 consecutive adult heart transplant recipients requiring peripheral VA-ECMO for PGD were included. Patients were divided according to arterial cannulation strategy into direct femoral cannulation (DFC, <i>n</i> = 25) and axillary Dacron graft cannulation (ADG, <i>n</i> = 17). Baseline recipient and donor characteristics, perioperative variables, postoperative outcomes, vascular complications, successful VA-ECMO weaning, and survival to hospital discharge were compared. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated for major clinical outcomes and cannulation-related complications. <b>Results:</b> The primary composite endpoint of cannulation-related complications occurred in 0/17 patients (0%) in the ADG group and 3/25 patients (12.0%) in the DFC group (OR 0.18, 95% CI 0.01-3.80; <i>p</i> = 0.260). Successful VA-ECMO weaning was achieved in 94.1% versus 92.0% (<i>p</i> = 1.000), and survival to hospital discharge was 76.5% versus 64.0% (OR 1.83, 95% CI 0.46-7.32; <i>p</i> = 0.505). Stroke occurred in 5.9% versus 16.0% (OR 0.33, 95% CI 0.03-3.23; <i>p</i> = 0.632), while renal replacement therapy was required in 35.3% versus 52.0% (OR 0.50, 95% CI 0.14-1.79; <i>p</i> = 0.353). No statistically significant differences were detected between groups. <b>Conclusions:</b> No statistically significant differences in successful VA-ECMO weaning or survival to hospital discharge were observed between axillary Dacron graft and direct femoral arterial cannulation. No statistically significant differences in neurological, vascular, or other major postoperative outcomes were detected. Although several complications occurred numerically less frequently with axillary cannulation, the limited sample size and wide confidence intervals preclude conclusions regarding comparative superiority. Axillary Dacron graft cannulation may therefore represent a feasible alternative in selected heart transplant recipients requiring peripheral VA-ECMO for PGD. Larger prospective multicenter studies are warranted.</p>","PeriodicalId":8937,"journal":{"name":"Biomedicines","volume":"14 10","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13702244/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149261890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BiomedicinesPub Date : 2026-10-21DOI: 10.3390/biomedicines14102406
Mei Chang, Jiaxuan Li, Feng Gu, Xin Wu, Bingyi Song, Zhouqing Chen, Zhong Wang
{"title":"Genetically Proxied SGLT2 Inhibition and Risk of Epilepsy: A Mediation Mendelian Randomization Study of Circulating Metabolites.","authors":"Mei Chang, Jiaxuan Li, Feng Gu, Xin Wu, Bingyi Song, Zhouqing Chen, Zhong Wang","doi":"10.3390/biomedicines14102406","DOIUrl":"10.3390/biomedicines14102406","url":null,"abstract":"<p><p><b>Background:</b> Epilepsy is a chronic neurological disorder that can significantly impair quality of life. Previous studies have demonstrated the positive effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on various systems, including the nervous system. SGLT2 inhibitors have been shown to reduce seizure activity in pentylenetetrazol-induced epilepsy models in rats. Recent study results showed that glucose-lowering drugs including SGLT2 inhibitors reduced risk of seizures and epilepsy. <b>Methods:</b> Genetic variants of SGLT2 inhibition were selected as exposure instrumental variables (IVs) and used type 2 diabetes (T2DM) as validation. Two-sample Mendelian Randomization (MR) analysis was conducted to explore the causal relationship between SGLT2 inhibition and epilepsy. In addition, we performed a two-step MR to evaluate whether possible circulating metabolites mediate the effects of SGLT2 inhibition on epilepsy. <b>Results:</b> The two-sample MR analysis showed that genetically proxied SGLT2 inhibition was associated with lower odds of epilepsy under MR assumptions [IVW: OR = 0.30 (95% CI: 0.13, 0.71), <i>p</i> = 0.0064]. Exploratory two-step analyses identified 3-methylglutaconate and N-acetylleucine as candidate metabolic signals; however, neither signal remained statistically significant after Benjamini-Hochberg correction. <b>Conclusion:</b> Our study suggests that SGLT2 is associated with a reduced risk of epilepsy, and the underlying mechanism may be the potential antioxidant and anti-inflammatory effects of SGLT2. In addition, circulating 3-methylglutaconate and N-acetylleucine should therefore be regarded as candidate metabolic signals rather than established mediators.</p>","PeriodicalId":8937,"journal":{"name":"Biomedicines","volume":"14 10","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13702378/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149261952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BiomedicinesPub Date : 2026-10-21DOI: 10.3390/biomedicines14102401
Manal A Nael, Laxman M Alakonda, Khaled M Elokely
{"title":"Advancing Drug Discovery Through Mechanistic Validation and Translational Evaluation.","authors":"Manal A Nael, Laxman M Alakonda, Khaled M Elokely","doi":"10.3390/biomedicines14102401","DOIUrl":"10.3390/biomedicines14102401","url":null,"abstract":"<p><p>The Special Issue \"Advances in Novel Drug Discovery, Synthesis, and Evaluation\" brings together five original research articles and one narrative review examining how experimental interventions might become useful therapies [...].</p>","PeriodicalId":8937,"journal":{"name":"Biomedicines","volume":"14 10","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13702532/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149261921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BiomedicinesPub Date : 2026-10-20DOI: 10.3390/biomedicines14102399
Meirambek Askarov, Ulpan Batenova, Ilona Pak, Elyarbek Tashmetov, Dmitriy Klyuyev, Min Sung Tak, Yevgeniy Kamyshanskiy
{"title":"Preoperative Skin Preconditioning with Autologous PRP and SVF: Effects on Cutaneous and Adnexal Repair in a Rabbit Pilot Study.","authors":"Meirambek Askarov, Ulpan Batenova, Ilona Pak, Elyarbek Tashmetov, Dmitriy Klyuyev, Min Sung Tak, Yevgeniy Kamyshanskiy","doi":"10.3390/biomedicines14102399","DOIUrl":"10.3390/biomedicines14102399","url":null,"abstract":"<p><p><b>Background:</b> Optimal healing of surgical skin wounds remains a critical issue in modern surgery. This study evaluated the effect of preoperative administration (before wound creation) of platelet-rich plasma (PRP) and stromal vascular fraction (SVF) on wound healing in a rabbit full-thickness excisional skin wound model. <b>Methods:</b> Forty animals were randomized into five groups: control (no treatment), 0.9% NaCl, SVF, PRP, and PRP + SVF. Biological agents were injected intradermally 24 h before standardized 2-cm excisional wounds were created. Histological, morphometric, IHC and contraction indices (SCI, DCI, WCI) were assessed at days 7, 14, and 30. <b>Results:</b> Preoperative administration of PRP + SVF significantly enhanced cutaneous wound repair, with early re-epithelialization evident by day 7 and complete epithelial restoration by day 14 compared with the control group. Histomorphometric analysis revealed that the PRP + SVF group demonstrated the highest angiogenic response on day 7 (median 24 vs. 12 in the control group, <i>p</i> = 0.027), the greatest regenerative tissue thickness on day 14 (84.5% vs. 62.5%, <i>p</i> = 0.021), and the highest extracellular matrix remodeling index on day 30 (0.655 vs. 0.404), accompanied by regeneration of skin appendages (median score 3 vs. 1 in the control group, <i>p</i> = 0.005). <b>Conclusions:</b> These findings demonstrate that preoperative administration of PRP combined with SVF improves the histological and histomorphometric outcomes of cutaneous wound healing. These preliminary findings provide a rationale for further experimental studies to validate and optimize this approach, to elucidate the underlying mechanisms, and to clarify the specific contribution of preoperative tissue conditioning.</p>","PeriodicalId":8937,"journal":{"name":"Biomedicines","volume":"14 10","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13702528/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149262014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}